ValiRx PLC Update on VAL401 - Peer-review Acceptance (7396K)
18 December 2018 - 6:00PM
UK Regulatory
TIDMVAL
RNS Number : 7396K
ValiRx PLC
18 December 2018
VALIRX PLC
("ValiRx" or the "Company")
UPDATE ON VAL401
"Acceptance of article for publication in the 'European Journal
of Drug Metabolism and Pharmacokinetics'.
"First peer-reviewed journal article accepted for publication
for VAL401 clinical trial results"
London, UK., 18 December 2018: ValiRx Plc (AIM: VAL), the
clinical stage biotechnology company, is pleased to announce the
acceptance for publication of the first article containing results
from the VAL401 clinical trial by the European Journal of Drug
Metabolism and Pharmacokinetics (an Adis journal in conjunction
with Springer Nature).
The peer-reviewed article will appear in the European Journal of
Drug Metabolism and Pharmacokinetics early in 2019. The article
details and analyses the pharmacokinetic data acquired during the
VAL401, Phase II clinical trial that was concluded in Tbilisi,
Georgia in 2017. VAL401 is a new formulation of the anti-psychotic
drug, risperidone, enabling our oncology treatment. This analysis
considers the clinical significance of the VAL401 results in
comparison to previously reported data for conventional
risperidone, providing a theoretical insight into the altered
activity of the therapeutic.
Dr Suzy Dilly, CEO of ValiSeek, commented: "I'm delighted to be
able to announce acceptance for publication of this article, which
is intended to be the first in a series of results-based
publications on VAL401. Peer-reviewed publications are always
interesting to complete, as the article is very much shaped and
expanded by the anonymous expert reviewers, providing a respected
validation of the data."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879 458
364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880
Adviser)
Liam Murray / Ludovico Lazzaretti
Novum Securities Limited Tel: +44 (0) 20 7399 9400
Colin Rowbury
Notes for Editors
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company
between ValiRx Plc and Tangent Reprofiling Limited, part of the
SEEK Group. ValiSeek was formed to progress the drug VAL401 through
its remaining preclinical development and towards Phase II trials
for the treatment of lung cancer and other oncology
indications.
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDFKODNABDDABD
(END) Dow Jones Newswires
December 18, 2018 02:00 ET (07:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024